TY  - JOUR
AU  - Grigorov, Ilijana
AU  - Pejić, Snežana
AU  - Todorović, Ana
AU  - Drakulić, Dunja
AU  - Veljković, Filip
AU  - Miletić Vukajlović, Jadranka
AU  - Bobić, Katarina
AU  - Soldatović, Ivan
AU  - Đurašević, Siniša
AU  - Jasnić, Nebojša
AU  - Stanković, Sanja
AU  - Glumac, Sofija
AU  - Mihailović-Vučinić, Violeta
AU  - Milenković, Branislava
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11550
AB  - The careful monitoring of patients with mild/moderate COVID-19 is of particular importance because of the rapid progression of complications associated with COVID-19. For prognostic reasons and for the economic management of health care resources, additional biomarkers need to be identified, and their monitoring can conceivably be performed in the early stages of the disease. In this retrospective cross-sectional study, we found that serum concentrations of high-mobility group box 1 (HMGB1) and heme oxygenase-1 (HO-1), at the time of hospital admission, could be useful biomarkers for COVID-19 management. The study included 160 randomly selected recovered patients with mild to moderate COVID-19 on admission. Compared with healthy controls, serum HMGB1 and HO-1 levels increased by 487.6 pg/mL versus 43.1 pg/mL and 1497.7 pg/mL versus 756.1 pg/mL, respectively. Serum HO-1 correlated significantly with serum HMGB1, oxidative stress parameters (malondialdehyde (MDA), the phosphatidylcholine/lysophosphatidylcholine ratio (PC/LPC), the ratio of reduced and oxidative glutathione (GSH/GSSG)), and anti-inflammatory acute phase proteins (ferritin, haptoglobin). Increased heme catabolism/hemolysis were not detected. We hypothesize that the increase in HO-1 in the early phase of COVID-19 disease is likely to have a survival benefit by providing protection against oxidative stress and inflammation, whereas the level of HMGB1 increase reflects the activity of the innate immune system and represents levels within which the disease can be kept under control.
T2  - International Journal of Molecular Sciences
T1  - Serum High-Mobility Group Box 1 and Heme Oxygenase-1 as Biomarkers in COVID-19 Patients at Hospital Admission
VL  - 24
IS  - 17
SP  - 13164
DO  - 10.3390/ijms241713164
ER  - 

@article{
author = "Grigorov, Ilijana and Pejić, Snežana and Todorović, Ana and Drakulić, Dunja and Veljković, Filip and Miletić Vukajlović, Jadranka and Bobić, Katarina and Soldatović, Ivan and Đurašević, Siniša and Jasnić, Nebojša and Stanković, Sanja and Glumac, Sofija and Mihailović-Vučinić, Violeta and Milenković, Branislava",
year = "2023",
abstract = "The careful monitoring of patients with mild/moderate COVID-19 is of particular importance because of the rapid progression of complications associated with COVID-19. For prognostic reasons and for the economic management of health care resources, additional biomarkers need to be identified, and their monitoring can conceivably be performed in the early stages of the disease. In this retrospective cross-sectional study, we found that serum concentrations of high-mobility group box 1 (HMGB1) and heme oxygenase-1 (HO-1), at the time of hospital admission, could be useful biomarkers for COVID-19 management. The study included 160 randomly selected recovered patients with mild to moderate COVID-19 on admission. Compared with healthy controls, serum HMGB1 and HO-1 levels increased by 487.6 pg/mL versus 43.1 pg/mL and 1497.7 pg/mL versus 756.1 pg/mL, respectively. Serum HO-1 correlated significantly with serum HMGB1, oxidative stress parameters (malondialdehyde (MDA), the phosphatidylcholine/lysophosphatidylcholine ratio (PC/LPC), the ratio of reduced and oxidative glutathione (GSH/GSSG)), and anti-inflammatory acute phase proteins (ferritin, haptoglobin). Increased heme catabolism/hemolysis were not detected. We hypothesize that the increase in HO-1 in the early phase of COVID-19 disease is likely to have a survival benefit by providing protection against oxidative stress and inflammation, whereas the level of HMGB1 increase reflects the activity of the innate immune system and represents levels within which the disease can be kept under control.",
journal = "International Journal of Molecular Sciences",
title = "Serum High-Mobility Group Box 1 and Heme Oxygenase-1 as Biomarkers in COVID-19 Patients at Hospital Admission",
volume = "24",
number = "17",
pages = "13164",
doi = "10.3390/ijms241713164"
}

Grigorov, I., Pejić, S., Todorović, A., Drakulić, D., Veljković, F., Miletić Vukajlović, J., Bobić, K., Soldatović, I., Đurašević, S., Jasnić, N., Stanković, S., Glumac, S., Mihailović-Vučinić, V.,& Milenković, B.. (2023). Serum High-Mobility Group Box 1 and Heme Oxygenase-1 as Biomarkers in COVID-19 Patients at Hospital Admission. in International Journal of Molecular Sciences, 24(17), 13164.
https://doi.org/10.3390/ijms241713164

Grigorov I, Pejić S, Todorović A, Drakulić D, Veljković F, Miletić Vukajlović J, Bobić K, Soldatović I, Đurašević S, Jasnić N, Stanković S, Glumac S, Mihailović-Vučinić V, Milenković B. Serum High-Mobility Group Box 1 and Heme Oxygenase-1 as Biomarkers in COVID-19 Patients at Hospital Admission. in International Journal of Molecular Sciences. 2023;24(17):13164.
doi:10.3390/ijms241713164 .

Grigorov, Ilijana, Pejić, Snežana, Todorović, Ana, Drakulić, Dunja, Veljković, Filip, Miletić Vukajlović, Jadranka, Bobić, Katarina, Soldatović, Ivan, Đurašević, Siniša, Jasnić, Nebojša, Stanković, Sanja, Glumac, Sofija, Mihailović-Vučinić, Violeta, Milenković, Branislava, "Serum High-Mobility Group Box 1 and Heme Oxygenase-1 as Biomarkers in COVID-19 Patients at Hospital Admission" in International Journal of Molecular Sciences, 24, no. 17 (2023):13164,
https://doi.org/10.3390/ijms241713164 . .